| Literature DB >> 25343521 |
Peter Gresner1, Jolanta Gromadzinska1, Ewa Jablonska1, Maciej Stepnik1, Oscar Zambrano Quispe2, Ewa Twardowska1, Wojciech Wasowicz1.
Abstract
Deleterious and missense mutations of RAD51C have recently been suggested to modulate the individual susceptibility to hereditary breast and ovarian cancer and unselected ovarian cancer, but not unselected breast cancer (BrC). We enrolled 132 unselected BrC females and 189 cancer-free female subjects to investigate whether common single nucleotide polymorphisms (SNPs) in non-coding regions of RAD51C modulate the risk of BrC, and whether they affect the level of oxidative stress and the extent/characteristics of DNA damage. Neither SNPs nor reconstructed haplotypes were found to significantly affect the unselected BrC risk. Contrary to this, carriers of rs12946522, rs16943176, rs12946397 and rs17222691 rare-alleles were found to present significantly increased level of blood plasma TBARS compared to respective wild-type homozygotes (p<0.05). Furthermore, these carriers showed significantly decreased fraction of oxidatively generated DNA damage (34% of total damaged DNA) in favor of DNA strand breakage, with no effect on total DNA damage, unlike respective wild-types, among which more evenly distributed proportions between oxidatively damaged DNA (48% of total DNA damage) and DNA strand breakage was found (p<0.0005 for the difference). Such effects were found among both the BrC cases and healthy subjects, indicating that they cannot be assumed as causal factors contributing to BrC development.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25343521 PMCID: PMC4208807 DOI: 10.1371/journal.pone.0110696
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Characteristics of the groups of subjects involved in the study.
| Feature | Cancer cases | Control subjects | DNA damage assay control subset |
| Total number | 132 | 189 | 40 |
| Age [years] | 57 [50–65] | 43 | 43 |
| Smoking status [never/ever] | 55/63 (47%/53%) | 120/68 (64%/36%) | 24/16 (60%/40%) |
| Pack-years | 11.3 [6.0–20.0] | 2.0 [1.0–4.6] | 1.0 [0.8–4.6] |
| Tumor staging | |||
|
| 44/45/1/6/1 | - | - |
|
| 44/24/10/2/20 | - | - |
| Tumor grade | |||
|
| 7/37/40/13 | - | - |
Numerical data for age and pack-years presented as median [interquartile range].
DNA damage assay control subset consisted of 40 subjects randomly selected from the whole control group by means of the age-stratified randomization;
p <<0.001 cancer cases vs. controls, Mann-Whitney U test;
p <0.005, cancer cases vs. controls; two-sided mid-P test;
p <<0.0001, cancer cases vs. controls, Mann-Whitney U test;
p <0.001, cancer cases vs. DNA damage assay control subset, Kruskal-Wallis H test post-hoc analysis;
Tumor staging classification: T – describes the size of the primary tumor and its invasiveness, N – describes the regional lymph nodes involved, x –data not available.
Resume of RAD51C SNPs analyzed in the study.
| Disruption of binding of selected nuclear transcription factors ( | |||||||||
| rs-code | New name | Other names | SNP position | MAF | NF-κB | Pax-5 | Bcl-6 | c-Myb | p53 |
| rs302874 | c.-2009C>T | g.3034C>T | 5′ near gene (promoter) | T: 0.42 | - | - | - | - | 0.0052 |
| rs12946522 | c.-1902T>G | g.3141T>G | 5′ near gene (promoter) | G: 0.17 | 0.0023 | - | 0.0028 | - | 0.0076 |
| rs302873 | c.-524C>G | g.4519C>G | 5′ near gene (promoter) | G: 0.41 | 0.0448 | 0.0698 | - | 0.0002 | - |
| rs16943176 | c.-118G>A | g.4925G>A | 5′ near gene (promoter) | A: 0.20 | 0.0133 | 0.0385 | 0.0391 | 0.0281 | 0.0490 |
| rs12946397 | c.-26C>T | g.5017C>T | exon 1 (5′UTR) | T: 0.21 | 0.0117 | 0.0642 | 0.0069 | - | 0.0196 |
| rs17222691 | c.145+947C>T | g.6134C>T | intron 1 | T: 0.20 | 0.0461 | 0.0051 | 0.0257 | 0.0131 | 0.0034 |
| rs28363302 | c.146-706delC | g.6624delC | intron 1 | del: 0.18 |
|
|
|
|
|
SNP nomenclature, localization and minor allele frequencies (MAF) are provided according to data obtained from the dbSNP database [31]. Additionally, the levels of significance (p-values) for observing the change in binding affinity between the RAD51C promoter and several well-known transcription factors caused by SNPs investigated in our study, as inferred by the is-rSNP algorithm [32] against the Transfac database [48] are also provided. Dash indicates that the given SNP is unlikely to affect the binding of given transcription factor. NA – not applicable.
Observed frequencies of genotypes and haplotypes reconstructed based on SNPs located within the LD block identified in RAD51C, together with respective odds ratios (OR) and corresponding 95% confidence intervals in BrC cases and healthy controls.
| SNP | BrC cases | Controls | OR [95% CI] | DNA damage control subset |
|
| ||||
| CC | 55 (0.42) | 69 (0.37) | A: 0.9 [0.7 – 1.3] | 16 (0.40) |
| CT | 56 (0.42) | 92 (0.49) | D: 0.8 [0.5 – 1.2] | 19 (0.48) |
| TT | 21 (0.16) | 27 (0.14) | R: 1.1 [0.6 – 2.1] | 5 (0.13) |
|
| ||||
| TT | 88 (0.67) | 119 (0.64) | A: 0.8 [0.5 – 1.2] | 29 (0.73) |
| TG | 41 (0.31) | 55 (0.29) | D: 0.9 [0.5 – 1.4] | 8 (0.20) |
| GG | 3 (0.02) | 13 (0.07) | R: 0.5 [0.1 – 1.8] | 3 (0.07) |
|
| ||||
| CC | 54 (0.41) | 68 (0.36) | A: 0.9 [0.7 – 1.2] | 15 (0.38) |
| CG | 56 (0.42) | 86 (0.46) | D: 0.8 [0.5 – 1.2] | 17 (0.42) |
| GG | 22 (0.17) | 34 (0.18) | R: 0.9 [0.5 – 1.6] | 8 (0.20) |
|
| ||||
| GG | 86 (0.65) | 118 (0.63) | A: 0.9 [0.6 – 1.3] | 30 (0.74) |
| GA | 43 (0.33) | 63 (0.34) | D: 0.9 [0.6 – 1.5] | 9 (0.23) |
| AA | 3 (0.02) | 7 (0.04) | R: 0.9 [0.2 – 3.7] | 1 (0.03) |
|
| ||||
| CC | 85 (0.64) | 119 (0.63) | A: 0.9 [0.6 – 1.4] | 30 (0.74) |
| CT | 44 (0.33) | 61 (0.32) | D: 1.0 [0.6 – 1.6] | 9 (0.23) |
| TT | 3 (0.02) | 8 (0.04) | R: 0.7 [0.2 – 2.9] | 1 (0.03) |
|
| ||||
| CC | 88 (0.67) | 119 (0.63) | A: 0.9 [0.6 – 1.3] | 30 (0.74) |
| CT | 41 (0.31) | 62 (0.33) | D: 0.9 [0.5 – 1.4] | 9 (0.23) |
| TT | 3 (0.02) | 7 (0.04) | R: 0.9 [0.2 – 3.7] | 1 (0.03) |
|
| ||||
| CC | 114 (0.86) | 152 (0.80) | A: 0.7 [0.4 – 1.2] | 32 (0.80) |
| C/del | 17 (0.13) | 36 (0.19) | D: 0.7 [0.4 – 1.4] | 8 (0.20) |
| del/del | 1 (0.01) | 1 (0.01) | R: 1.3 [0.1 – 21.5] | 0 (0.00) |
|
|
|
|
| |
|
| 214 (0.811) | 298 (0.793) | 1.1 [0.8 – 1.7] | - |
|
| 47 (0.178) | 76 (0.202) | 0.9 [0.6 – 1.3] | - |
|
| 2 (0.008) | 0 (0.000) |
| - |
|
| 1 (0.004) | 1 (0.003) | 1.4 [0.04 – 55.8] | - |
|
| 0 (0.000) | 1 (0.003) |
| - |
Data presented as absolute (relative) frequencies of individual genotypes observed in BrC cases, controls and in subjects randomized into DNA damage control subset. NA – not applicable.
Genetic model employed in order to analyze the association between genotype distribution and cancer: A – direct comparison of the frequency of alleles; D – dominant genetic model; R – recessive genetic model;
OR values adjusted for age and smoking status, together with 95% CI determined by logistic regression;
Significant differences in genotype distributions between the whole control group and the DNA damage control subjects were sought for by the generalized Fisher exact (Fisher-Freeman-Halton) test. No significant differences were found;
OR values and 95% CI determined by two-sided exact mid-P test.
Figure 1The map of LD between seven analyzed SNPs in non-coding regions of RAD51C.
The values in the map are the normalized measures of allelic association |D’| (A) and correlation coefficients (r2) (B) calculated for each pair of SNPs (both provided as percentages). The color scheme represent the corresponding confidence bounds for a given pair of SNPs: black – strong evidence of LD; grey – inconclusive; white – strong evidence of recombination [37]. Solid line indicates the identified 1 kb-long LD block, within which common and rare haplotypes were reconstructed, the frequency of which is provided in the Table 3. Algorithm employed for LD block identification is described in the section.
Figure 2Levels of TBARS (dark columns), DNA strand breakage (grey columns) and total DNA damage (white columns) determined in whole blood samples from BrC cases and healthy control females.
Data presented as medians (columns) and interquartile ranges (whiskers). Levels of TBARS among BrC cases (n = 132) vs. control females (n = 189): 2.6 [2.1–3.3] μM vs. 2.3 [1.8–2.7] μM, p<0.0001, Mann-Whitney U test (***). Levels of DNA strand breakage and total DNA damage were assessed in the whole group of BrC cases and tested for differences against a subset of 40 control subjects randomly selected from the whole control group by means of the age-stratified randomization (see ). DNA strand breakage: BrC cases vs. controls: 2.0 [1.5–2.7] %DNA in comet tail vs. 1.6 [1.1–2.1] %DNA in comet tail, p<0.001, Mann-Whitney U test (**). Total DNA damage: BrC cases vs. controls: 3.5 [2.9–4.6] %DNA in comet tail vs. 3.5 [2.4–4.6] %DNA in comet tail, NS. The age distribution in the control subset was verified to match with the one in the whole control group (see ). The distribution of TBARS in the randomized subset of 40 controls did not differ significantly from the one observed in the whole control group (1.7 [1.5–2.1] μM vs. 2.3 [1.8–2.7] μM, NS) but differed significantly from the one in the BrC group (1.7 [1.5–2.1] μM vs. 2.6 [2.1–3.3] μM, p<0.001, Kruskal-Wallis H-test post-hoc analysis).
Effect of RAD51C SNPs and BrC on blood plasma log-levels of TBARS.
| A | |||||||
| TBARS [log-μM] | |||||||
| Controls | rs302874 | rs12946522 | rs302873 | rs16943176 | rs12946397 | rs17222691 | rs28363302 |
|
| 0.37±0.12 | 0.31±0.11 | 0.37±0.12 | 0.32±0.11 | 0.32±0.11 | 0.32±0.11 | 0.35±0.14 |
| heterozygotes | 0.33±0.13 | 0.44±0.12 | 0.33±0.13 | 0.43±0.12 | 0.43±0.12 | 0.43±0.12 | 0.35±0.14 |
|
| 0.36±0.15 | 0.29±0.04 | 0.36±0.14 | 0.27±0.13 | 0.27±0.13 | 0.27±0.13 | 0.54 |
| heterozygotes & | 0.34±0.13 | 0.42±0.13 | 0.34±0.13 | 0.42±0.13 | 0.42±0.13 | 0.42±0.13 | 0.35±0.11 |
|
| |||||||
|
| 0.40±0.15 | 0.39±0.14 | 0.40±0.15 | 0.39±0.15 | 0.39±0.15 | 0.40±0.15 | 0.42±0.15 |
| heterozygotes | 0.42±0.17 | 0.44±0.18 | 0.41±0.16 | 0.44±0.17 | 0.44±0.17 | 0.43±0.17 | 0.38±0.12 |
|
| 0.42±0.16 | 0.48±0.20 | 0.44±0.17 | 0.48±0.20 | 0.48±0.20 | 0.48±0.20 | 0.32 |
| heterozygotes & | 0.42±0.16 | 0.45±0.18 | 0.42±0.16 | 0.45±0.17 | 0.45±0.17 | 0.44±0.17 | 0.36±0.11 |
(A) Log-transformed levels of TBARS in blood plasma of healthy controls and BrC cases by carried genotype. (B) Summary of the analysis of main effects of RAD51C SNP and BrC on blood plasma levels of TBARS, adjusted to subjects' age and lifetime smoking. In each column data are presented as means ± SD. Identification of genotypes as wild-type (wt)-homozygotes, heterozygotes and rare homozygotes with reference to Table 3, in which individual genotypes for each SNP are ordered accordingly. The levels of significance of main effects and post-hoc multiple comparisons were inferred by ANCOVA and the Scheffé test, respectively. Main effects: a p <0.05 and p <0.01 under additive and dominant model, respectively; b p <0.05 under additive and dominant models; c p <0.05 under dominant model; Post-hoc comparisons: d p <0.05 compared to wt-homozygotes; e p <0.01 compared to wt-homozygotes; f p <0.05 compared to wt-homozygotes.
Figure 3Log-transformed levels of total DNA damage (A) and DNA strand breakage (B) expressed as logarithmically-transformed relative amount of DNA in respective comet tails in whole blood leukocytes of healthy controls (solid) and BrC cases (stripes) carrying the respective wild-type (wt-; dark columns) or rare-allele containing (var-; light columns) genotypes.
Only dominant genetic model was assumed. Identification of genotypes as wild-type or rare-allele containing (i.e. heterozygotic and rare homozygotes) with reference to Table 3, in which individual genotypes for each SNP are ordered accordingly. Data are presented as means (columns) ± SD (error bars). Logarithmical transformation was employed in order to normalize the distribution of raw comet assay data for the purpose of ANOVA/ANCOVA analysis. Total DNA damage data for wt-controls, var-controls, wt-cases and var-cases, respectively (log-%): rs302874: 0.56±0.17, 0.47±0.24, 0.57±0.16, 0.55±0.19; rs12946522: 0.49±0.23, 0.50±0.25, 0.57±0.17, 0.53±0.19; rs302873: 0.56±0.17, 0.47±0.24, 0.57±0.16, 0.55±0.19; rs16943176: 0.50±0.23, 0.50±0.25, 0.57±0.18, 0.53±0.18; rs12946397: 0.50±0.23, 0.50±0.25, 0.57±0.18, 0.53±0.18; rs17222691: 0.50±0.23, 0.50±0.25, 0.57±0.18, 0.54±0.17; rs28363302: 0.49±0.21, 0.54±0.38, 0.55±0.18, 0.64±0.14. DNA strand breakage data wt-controls, var-controls, wt-cases and var-cases: rs302874: 0.17±0.25, 0.15±0.18, 0.35±0.19, 0.26±0.18; rs12946522: 0.15±0.20, 0.21±0.21, 0.29±0.19, 0.32±0.18; rs302873: 0.17±0.25, 0.15±0.18, 0.35±0.19, 0.27±0.18; rs16943176: 0.14±0.20, 0.21±0.21, 0.29±0.19, 0.32±0.18; rs12946397: 0.14±0.20, 0.21±0.21, 0.29±0.19, 0.31±0.18; rs17222691: 0.14±0.20, 0.21±0.21, 0.29±0.19, 0.32±0.18; rs28363302: 0.17±0.20, 0.06±0.20, 0.28±0.19, 0.40±0.16. See Table 5 for the summary of statistical analysis.
Summary of the analysis of effect of RAD51C SNPs and BrC on DNA damage.
| A | Total DNA damage [log-% DNA] | ||||||
|
| |||||||
| Controls | 0.50±0.23 | ||||||
| BrC cases | 0.56±0.18 | ||||||
|
|
|
|
|
|
|
|
|
|
| 0.57±0.16 | 0.56±0.19 | 0.57±0.16 | 0.56±0.19 | 0.56±0.19 | 0.55±0.19 | 0.54±0.19 |
| heterozygotes & | 0.54±0.20 | 0.53±0.20 | 0.54±0.20 | 0.53±0.19 | 0.53±0.19 | 0.53±0.18 | 0.63±0.18 |
The summary of analysis of main effects of RAD51C SNPs and BrC on total DNA damage (A) and DNA strand breakage (B) adjusted to subjects' age and blood plasma TBARS. In each column, logarithmically-transformed data are presented as means ± SD. Identification of subjects as wild-type (wt)-homozygotes, heterozygotes and rare homozygotes with reference to Table 3, in which individual genotypes for each SNP are ordered accordingly. Only dominant genetic model was assumed in the analysis. The levels of significance of main effects and post-hoc multiple comparisons were inferred by ANCOVA and the Scheffé test, respectively. Main effects (asterisks): * p <0.01; Post-hoc comparisons (letters): a p <0.005 compared to controls.
The effect of RAD51C SNPs and BrC on ratio of oxidatively generated DNA damage to DNA strand breakage.
| A |
| ||||||
| rs302874 | rs12946522 | rs302873 | rs16943176 | rs12946397 | rs17222691 | rs28363302 | |
|
| |||||||
|
| 0.18±0.63 | 0.19±0.48 | 0.18±0.63 | 0.22±0.47 | 0.22±0.47 | 0.22±0.47 | 0.03±0.49 |
| heterozygotes & | 0.06±0.51 | −0.19±0.63 | 0.06±0.51 | −0.19±0.63 | −0.19±0.63 | −0.19±0.63 | 0.45±0.75 |
| BrC cases | |||||||
|
| −0.27±0.43 | −0.08±0.34 | −0.25±0.43 | −0.08±0.34 | −0.09±0.34 | −0.10±0.37 | −0.17±0.41 |
| heterozygotes & | −0.09±0.37 | −0.33±0.47 d | −0.10±0.38 | −0.31±0.47 d | −0.30±0.47 | −0.29±0.44 | −0.16±0.36 |
(A) Values of the ratio of oxidatively generated DNA damage to DNA strand breakage R in whole blood leukocytes of healthy controls and BrC cases, classified by carried genotype. (B) Summary of the analysis of main effects of RAD51C SNPs and BrC on R ratio adjusted to subjects' age and TBARS. Provided are the logarithmically-transformed values of R defined as FPG[%DNA]/SSB[%DNA]-1. Data are presented as means ± SD. Identification of subjects as wild-type (wt)-homozygotes, heterozygotes and rare homozygotes with reference to Table 3, in which individual genotypes for each SNP are ordered accordingly. Only dominant genetic model was assumed in the analysis. The levels of significance of main effects and post-hoc multiple comparisons were inferred by ANCOVA (with adjustment to subjects' age and blood plasma TBARS) and the Scheffé test, respectively. Main effects (asterisks): * p <0.01; ** p <0.005; Post-hoc comparisons (letters): a p <0.0005 compared to wt-homozygotes; b p <0.001 compared to wt-homozygotes; c p <0.005 compared to wt-homozygotes; d p <0.05 compared to wt-homozygotes.